Tag: months

Company is in the process of AI integration with the aim of faster market capture and more efficient operation

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of its common stock (or common stock equivalents in lieu thereof) together with Series C warrants to purchase up to 20,000,000 shares of common stock (the "Series C Warrants") and Series D warrants to purchase up to 20,000,000 shares of common stock (the "Series D Warrants"), at a combined offering price of $0.50 per share and accompanying warrants, for aggregate gross proceeds of approximately $10 million before deducting placement agent fees and other offering expenses.

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR), today announced that the Toronto Stock Exchange (the “TSX”) has approved the Company’s notice of intention to renew its normal course issuer bid (the “NCIB”) for common shares of the Company (the “Common Shares”).

CALGARY, Alberta, June 26, 2025 (GLOBE NEWSWIRE) -- Petrus Resources Ltd. ("Petrus") (TSX: PRQ) is pleased to announce that the Toronto Stock Exchange (the "TSX") has accepted Petrus' notice of intention to renew its normal course issuer bid (the "NCIB"). The NCIB allows Petrus to purchase up to 6,448,237 common shares (representing 5% of Petrus' outstanding common shares as of June 18, 2025) over a period of twelve months commencing on June 30, 2025. On June 18, 2025, Petrus had 128,964,754 common shares outstanding. The NCIB will expire no later than June 29, 2026.

ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy^® 2 mg (the trade name for neffy^® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions.